Naringenin-loaded TPGS polymeric nanosuspension: In-vitro and in-vivo anti-inflammatory activity

Abstract

Naringenin, (NAR) from Citrus grandis (L.) Osbeck, family Rutaceae, exhibit extensive pharmacological action, lacks significance in application due to low aqueous solubility approximately 0.214mg/mL, which results in low bioavailability (5.8%). Nanosuspension of NAR (NARNS) was prepared with various concentrations of polymers by high pressure homogenization technique. Physicochemical properties of the formulations were studied and optimized in our previous studies. The present study was performed further to identify the anti-inflammatory activity of the NARNS formulation in comparison with standard drug and NAR. Denaturation of protein and membrane stabilization methods were chosen for in-vitro evaluation and in-vivo studies performed were acute inflammatory studies (carrageenan-induced paw edema) and chronic inflammatory studies (cotton pellet granuloma) on Wistar albino rats. The optimum concentration of stabilizer and co-stabilizer chosen for this study was 1:1.5:1 with ps 80.52±0.13 with better solubility when compared to NAR. The studies demonstrated significantly greater anti-inflammatory activity of NARNS compared to NAR and the standard drug at a lower concentration.